ORIC Pharmaceuticals reported second quarter 2026 financial results and operational updates. The company initiated the global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), enrolling approximately 600 patients, with Bayer providing darolutamide at no cost under a collaboration agreement. Cash and investments totaled $387.6 million as of June 30, 2026, including $59.9 million from ATM proceeds, funding operations into the second half of 2028. R&D expenses were $36.3 million for the quarter, while net loss was $41.5 million. The company anticipates a rinzimetostat program update in late 2026 and enozertinib data presentations in October 2026. ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing oncology treatments to overcome therapeutic resistance.

On July 28, 2026, ORIC Pharmaceuticals' Board approved the Amended and Restated 2022 Inducement Equity Incentive Plan, increasing reserved shares by 1,100,000 to a total of 3,350,000. This action was taken without stockholder approval under Nasdaq Listing Rules to facilitate equity awards for new hires or merger-related acquisitions. The company operates in the biopharmaceutical industry.

ORIC Pharmaceuticals, Inc. held its annual meeting of stockholders on June 18, 2026, where shareholders approved the amendment and restatement of the 2020 Equity Incentive Plan. Key changes to the plan include reducing the annual evergreen increase from 5% to 4% of outstanding common stock, removing a fixed 2,656,500 share annual limit, and setting a maximum cap of 10,000,000 shares for incentive stock options. Additionally, the company elected Jacob M. Chacko and Mardi C. Dier as Class III directors, ratified KPMG LLP as the independent auditor, and approved annual advisory votes on executive compensation. The company is a biopharmaceutical firm focused on developing oncology therapies.